Covid-19 roundup: Parsing Bourla, a top analyst sees improved chances for Pfizer vaccine; Fauci: No surprise that Trump was hit by Covid-19
With a medley of adverse events hobbling the late-stage development of vaccines and drugs, Pfizer CEO Albert Bourla’s latest — extended — timeline for the mRNA approach they’re working on with BioNTech is giving some top analysts added confidence that the pharma giant can come up with the regulatory goods next month.
Parsing Bourla’s language in his comments last week, SVB Leerink’s Geoffrey Porges notes that Bourla’s decision to say they “may” be able to nail down the positive efficacy of their vaccine in a matter of days — a big change from his earlier certainty — may also indicate a delay on that to early November.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.